Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China

NCT ID: NCT02631317

Last Updated: 2016-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2178 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PROMISE is a prospective, nationwide, multicenter, longitudinal cohort study, focusing on hospital intravenous thrombolysis process reengineering for acute ischemic stroke (AIS). With a proposed "Reengineered Process Framework" for intravenous thrombolysis process by the PROMISE study steering committee, about 30 medical centers enters would be recruited nationwide, and each center would include consecutive AIS patients with an onset-to-door time (ODT) of less than 3.5 h. The investigators hypothesize that the proposed "Reengineered Process Framework" is suitable and feasible for hospitals in mainland of China; the rate of intravenous rt-PA thrombolysis in ischemic stroke patients with an ODT of less than 3.5 h would be more than 20% or be increased by 40% as compared with baseline; the proportion of patients with a door-to-needle (DNT) time of less than 60 min would be more than 20%, or be with an increase by ≥ 40% as compared with baseline.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. After reviewing domestic and international clinical research literature, the PROMISE study steering committee constructed the "Reengineered Process Framework" for intravenous thrombolysis process with business process reengineering theory. The suggested "Reengineered Process Framework" is regarded as feasible and suitable for hospitals in mainland of China.
2. The study period is 12 months, of which the first 3 months is the baseline period. After 3 months, all centers should develop new thrombolytic processes according to the "Reengineered Process Framework". The new processes are gradually implemented since the 4th month with continues care quality improvements.
3. The "Reengineered Process Framework" adopts a form of comprehensive package, proposes unified key points of process reengineering, provides a series of supporting, standardized tools for process management, and establishes a real-time key performance indicator (KPI) monitoring feedback system, etc.
4. Supporting, standardized tools includes: rapid identification tools of suspected stroke for medical personnel in the emergency system; stroke team building programs; real-time feedback form of KPI; standardized thrombolysis informed consent form and informed conversation public service advertising posters; suggested indications and contraindications for intravenous thrombolysis; standard operation procedure of intravenous rt-PA thrombolysis, etc.

With these methods, it is expected to raise the thrombolytic rate for patients arrived at medical center within 3.5 hours after the onset, and to shorten the door to needle time in China.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke Adverse Effect of Thrombolytic Drugs, Sequela

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rt-PA

patients treated with rt-PA, followed strategies were used: advance hospital notification by EMS, stroke team notification, key performance indicators feedback form, standard informed consent procedures, performance of thrombolysis at CT-room.

Advance hospital notification by EMS

Intervention Type BEHAVIORAL

Advance hospital notification by EMS

stroke team notification

Intervention Type BEHAVIORAL

stroke team notification

key performance indicators feedback form

Intervention Type BEHAVIORAL

a "key performance indicators real-time feedback form" as continuing quality improvement

standard informed consent procedures

Intervention Type BEHAVIORAL

standard informed consent procedures with public poster of thrombolysis

performance of thrombolysis at CT-room

Intervention Type BEHAVIORAL

performance of thrombolysis at CT-room or emergency room

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Advance hospital notification by EMS

Advance hospital notification by EMS

Intervention Type BEHAVIORAL

stroke team notification

stroke team notification

Intervention Type BEHAVIORAL

key performance indicators feedback form

a "key performance indicators real-time feedback form" as continuing quality improvement

Intervention Type BEHAVIORAL

standard informed consent procedures

standard informed consent procedures with public poster of thrombolysis

Intervention Type BEHAVIORAL

performance of thrombolysis at CT-room

performance of thrombolysis at CT-room or emergency room

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All AIS patients with an onset-to-door time of less than 3.5 h of onset; informed consent

Exclusion Criteria

1. Complete remission of symptoms and signs, in consideration for patients with transient ischemic attack;
2. Silent cerebral infarction without symptoms or signs;
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital of Jinan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anding Xu

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ANDING XU, Prof

Role: STUDY_CHAIR

Stroke Center, The First Affiliated Hospital,Jinan University Guanzghou

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011BAI08B02-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hemoadsorption for Severe Ischemic Stroke
NCT07127484 NOT_YET_RECRUITING NA
Precision Medicine in Stroke
NCT05815836 COMPLETED